Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.12    
    

AMENDMENT TO LICENSE AGREEMENT

HAVING AN EFFECTIVE DATE OF MARCH 7, 2007

BETWEEN

CALIFORNIA INSTITUTE OF TECHNOLOGY

and

HELICOS BIOSCIENCES CORPORATION  

        This Amendment to the License Agreement dated November 30, 2003 ("Agreement"), is effective as of the 7th day of March, 2007, by and between the California
Institute of Technology, 1200 East California Boulevard, Pasadena, California 91125 ("Caltech") and Helicos Biosciences Corporation, a corporation having a principal place of business at 150 Cambridge
Park Drive, Cambridge, MA 02140 ("Licensee"). 

        WHEREAS,
Professor Stephen Quake, currently of Stanford University and formerly of Caltech, became a Howard Hughes Medical Institute ("HHMI") investigator at Stanford on
January 16, 2006, and is subject to HHMI policies on and after such date, which, among other things, restrict the granting of future rights in intellectual property developed in his laboratory;
and 

        WHEREAS,
Professor Milan Mrkisch of the University of Chicago became a HHMI investigator on September 1, 2005 and is subject to HHMI policies on and after such date, which, among
other things, restrict the granting of future rights in intellectual property developed in his laboratory; and 

        WHEREAS,
[***] is co-owned by Caltech, Stanford University, and the University of Chicago; and 

        WHEREAS,
Caltech, Stanford University, and the University of Chicago have agreed that Caltech shall represent their respective interests in licensing [***] in the
Inter-Institutional Agreements attached as Exhibits B and C, and for said patent, Caltech's rights are understood to include those of Stanford University and the University of Chicago; and 

        WHEREAS,
[***] is not included in the Improvement Patent Rights because of its invention outside the laboratories of Profs. Stephen Quake and Brian Stoltz at
Caltech. 

        WHEREAS,
both Licensee and Caltech now desire to amend the Agreement to include [***], in addition to other patent applications owned solely by Caltech. 

        NOW,
THEREFORE, the parties hereby agree, as follows: 

	1.
	All
capitalized terms used herein and not otherwise defined herein shall have the respective meanings assigned thereto in the Agreement.

	2.
	Exhibit A
of the Agreement is replaced by the Exhibit A attached herein.

	3.
	In
exchange for the addition of [***] to the Exclusively Licensed Patent Rights, Licensee shall pay Caltech a one-time license fee of $50,000, due
and payable on April 7, 2007.

	4.
	Section 1.6
of the Agreement is replaced by the following Section 1.6: 

1.6    "Exclusively Licensed Patent Rights" means Caltech's rights under: (a) all patents and patent applications listed in
Exhibit A attached hereto and Improvement Patent Rights thereof; (b) any patents issuing therefrom; and (c) any patents or patent applications claiming a right of priority thereto
(including reissues, reexaminations, renewals, extensions, divisionals, continuations, continuations-in-part [***], and foreign counterparts of any of
the foregoing). 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

 
	5.
	Section 1.9
of the Agreement is replaced by the following Section 1.9: 

1.9    "Improvements" means any future invention conceived and reduced to practice or otherwise developed in the laboratory of Stephen Quake
or Brian Stoltz at Caltech, either solely or jointly with Licensee in the Field, for a period of (3) years from the Effective Date (the "Improvements Period") and which are dominated by a Valid
Claim or which embody the Caltech Technology. The parties agree to negotiate in good faith, at the request of the Licensee, prior to the expiration of the Improvements Period to extend the
Improvements Period to no less than five (5) years from the Effective Date. Improvements shall expressly exclude any invention which (a) is dominated by a Valid Claim of a patent or
patent application claiming priority to [***]; (b) was conceived after September 15, 2005. 

	6.
	Section 2.2
of the Agreement is replaced by the following Section 2.2: 

2.2    Reservation of Rights; Government Rights. These licenses are subject to any existing right of the US Government under Title 35, United
States Code, Section 200 et seq. and under 37 Code of Federal Regulations, Section 401 et seq., including but not limited to the grant to the U.S. Government of a nonexclusive,
nontransferable, irrevocable, paid-up license to practice or have practiced any invention conceived or first actually reduced to practice in the performance of work for on behalf of the
U.S. Government throughout the world. 

Licensee
agrees that all Licensed Products covered by an Exclusively Licensed Patent Right, and to be sold, licensed, distributed, or used by on or behalf of Licensee and Affiliates in the United
States, shall be manufactured substantially in the United States to the extent (if at all) required by 35 U.S.C. Section 204. 

Caltech
retains the right, on behalf of themselves and all other non-profit academic research institutions, to practice the Exclusively Licensed Patent Rights under patents claiming
priority
to [***] for any non-profit purpose, including sponsored research and collaborations. Licensee has no right to enforce the Exclusively Licensed Patent Rights under
patents claiming priority to [***] against any such institution. Caltech and any such other institution have the right to publish any information included in the Exclusively
Licensed Patent Rights under patents claiming priority to [***], or any Technology associated with [***]. 

Rights
not explicitly granted are reserved by Caltech. 

	7.
	Section 11.2
of the Agreement is replaced by the following Section 11.2: 

11.2    Permitted Disclosures. Notwithstanding the foregoing, each party may disclose: (a) confidential information as required by
securities or other applicable laws or pursuant to governmental proceedings, provided that the disclosing party gives advance written notice to the other party and reasonably cooperates therewith in
limiting the disclosure to only those third parties having a need to know; and (b) confidential information to that party's actual or prospective investors or corporate partners, or to that
party's accountants, attorneys, and other professional advisors; and (c) the fact that Licensee has been granted a license under the Exclusively Licensed Patent Rights; and (d) this
Agreement and such other documents or records relating to this Agreement as HHMI may reasonably request, including without limitation any royalties in the form of equity allocable to Profs. Quake and
Mrkisch or other HHMI employees, subject in each case to HHMI's obligations to maintain them in confidence. Except with respect to the above third parties, Licensee aggress not to disclose information
described in paragraph 11.1 to any third party unless under an appropriate nondisclosure agreement. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

2

 
	8.
	Section 11.3
is added to the Agreement: 

11.3    Licensor and HHMI Identification. Licensee is not permitted to identify Stanford, Caltech, or the University of Chicago in any
promotional statement, or otherwise use the name of any Stanford, Caltech, or University of Chicago faculty member, employee, or student, or any trademark, service mark, trade name, or symbol of
Caltech, Stanford or Stanford Hospitals and Clinics, including the Stanford and Caltech name, unless Licensee has received Stanford's or Caltech's or the University of Chicago's prior written consent,
as the case may be. Permission to Licensee may be withheld at Stanford's or Caltech's or University of Chicago's sole discretion. Should Licensee wish to identify HHMI or any HHMI employee (including
Profs. Quake and Mrkisch) in any promotional statement, or otherwise use HHMI's name or that of any HHMI employee such as Profs. Quake and Mrkisch, Licensee shall first obtain HHMI's (and Profs.
Quake's and Mrkisch's, if applicable) prior written consent. 

	9.
	Section 13.1
of the Agreement is replaced by the following Section 13.1: 

13.1    Indemnification. Licensee agrees that Caltech, Stanford, and the University of Chicage (including their trustees, officers, faculty
and employees) shall have no liability to Licensee, its Affiliates, their customers or any third party, for any claims, demands, losses, costs, or other damages which may result from personal injury,
death, or property damage related to the Licensed Products ("Product Liability Claims"). Licensee agrees to defend, indemnify, and hold harmless Caltech, Stanford, and the University of Chicage; and
their trustees, officers, faculty and employees from any such Product Liability Claims, provided that: (a) Licensee is notified promptly of any Product Liability Claims; (b) Licensee has
the sole right to control and defend or settle any litigation within the scope of this indemnity; and (c) all indemnified parties cooperate to the extent necessary in the defense of any Claims. 

	10.
	[***] 

        In Witness Whereof, the parties have caused this 3rd Amendment to be executed: 

	California Institute of Technology	 	Helicos Biosciences Corporation (Licensee)
	

By:	
 	

/s/  FRED FARINA      	
 	

By:	
 	

/s/  THOMAS MEYERS      
	 	 	
 Fred Farina

Asst. VP, Office of Technology Transfer	 	 	 	
 Thomas Meyers

General Counsel
	 	 	    California Institute of Technology	 	 	 	    Helicos Biosciences Corporation

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

3

 
Exhibit A

Exclusively Licensed Patent Rights  

[***] 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

4

  

 
 

INTER-INSTITUTIONAL AGREEMENT    
    

        This Inter-Institutional Agreement ("Agreement") is made and entered into this 20th day of July, 2006 ("Effective Date") by and between CALIFORNIA
INSTITUTE OF TECHNOLOGY ("Caltech"), a corporation duly organized and existing under the laws of California and having its principal office at 1200 East California Boulevard, Pasadena, California
91125, and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ("Stanford"), an institution of higher education having powers under the laws of the State of California and having its
principal office at 1705 El Camino Real, Palo Alto, CA 94306-1106. 

 
 

RECITALS    
    

        WHEREAS, Professor Stephen Quake has worked at Caltech and Stanford in the development of technology, further identified as Exhibit A; and 

        WHEREAS,
Stanford wishes Caltech to represent Stanford's interests in the filing, prosecution and maintenance of all patents covering inventions described in Patent Rights; and 

        WHEREAS,
Stanford wishes Caltech to represent Stanford's interests in licensing of the Patent Rights; and 

        WHEREAS,
Professor Stephen Quake ("Dr. Quake") became a Howard Hughes Medical Institute ("HHMI") investigator at Stanford on January 16, 2006, and is subject to HHMI
policies on and after such date, which, among other things, restrict the granting of future rights in intellectual property developed in his laboratory; and 

        WHEREAS,
Stanford and Caltech want the inventions described in Patent Rights to be patented and licensed to the fullest extent so the commercial products and other benefits from
licensing it can be enjoyed by the general public; 

        The
parties agree as follows: 

1.     DEFINITIONS  

	1.1
	"Patent(s)"
means rights under all domestic and foreign patents and patent applications listed in Exhibit A attached hereto and all patents and patent applications that
describe and claim inventions set forth in the invention disclosures listed on Exhibit A; and patents which issue on the applications listed in Exhibit A or any applications that claim
inventions set forth in the invention disclosures set for on Exhibit A; all reissues, reexaminations, renewals, extensions, divisionals, and continuations of the foregoing patents and patent
applications; and any foreign counterparts and any other forms of protection directed to the inventions described and claimed in the patents or patents or patent applications and inventions
disclosures listed in Exhibit A.

	1.2
	"Patent
Rights" means worldwide rights to the inventions described and claimed in the patent applications listed in Exhibit A; reissues, reexaminations, renewals, extensions,
divisionals, and continuations of the foregoing; and any foreign counterparts and any other forms of protection directed to the inventions described and claimed in the patent applications listed in
Exhibit A. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

1

 

	1.3
	"Technology"
means all proprietary information, know-how, procedures, methods, prototypes, designs, technical data and reports listed in Exhibit A that were in
existence on or prior to March 1, 2006 and are necessary or useful in the development of Licensed Products and which relate to the Licensed Products, but which are not the subject of the Patent
Rights. Subject to the foregoing, inventions which (i) are described and claimed in the applications for patents listed in Exhibit A and (ii) are not claimed in an issued patent
included in the Licensed Patent Rights shall be considered to be Technology.

	1.4
	"Net
Income" means royalties and fees and any other consideration, including but not limited to equity, received from licensing of Patent Rights less, where applicable, any
out-of-pocket expenses of the parties associated with Patent Rights or the License Agreement.

	1.5
	"Licensee"
means any party to a License Agreement with Caltech.

	1.6
	"License
Agreement" means any agreement entered into by Caltech on behalf of both Stanford and Caltech that grants Licensee the right to make, use, offer to sell and/or sell products
or services covered by Patent Rights, or any agreement granting an option for such a license.

	1.7
	"Inventors"
means Stephen Quake of Caltech and Stanford, Jerrod Schwartz of Caltech and Stanford; Milan Mrksich of University of Chicago, either together individually.

	1.8
	"Patent
Prosecution" means the preparation, filing, prosecution, maintenance and/or defense of Patent(s).

	1.9
	"License
Expenses" means all reasonable, out-of-pocket expenses incurred by Caltech related to Patent Prosecution. 

2.     PATENT PROSECUTION AND PROTECTION  

	2.1
	Caltech
may file patent applications covering the Patent Rights and will provide to Stanford all serial numbers and filing dates, together with copies of all the applications,
including copies of all office actions, responses and all other communications from the U.S. Patent and Trademark Office.

	2.2
	Caltech
will, after consulting with Stanford, and if necessary after consulting with Licensee, make an election whether, when, and in which countries, it wishes to file foreign patent
applications. Caltech will notify Stanford in writing, of its election regarding foreign filing. If foreign patent applications are filed, Caltech will provide to Stanford copies of foreign patent
applications and patent office actions as Stanford may request in the course of prosecution.

	2.3
	Caltech
will record assignments of domestic Patent Rights in the United States Patent and Trademark Office and will provide Stanford with a photocopy of each recorded assignment.
Stanford inventors will assign to Stanford and Caltech inventors will assign to Caltech.

	2.4
	Notwithstanding
any other provision of this Agreement, Caltech will not abandon the prosecution of any patent application (except for purposes of filing continuation applications) or
the maintenance of any Patent Rights without prior written notice to Stanford in which case Stanford may assume responsibility of the same.

	2.5
	Caltech
will promptly provide Stanford with copies of all patents issued under Patent Rights. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

2

 

	2.6
	Caltech
will invoice Stanford for reimbursement of one-third of the unreimbursed costs of filing and prosecuting Patent Rights during the term of this Agreement, or, in
the event a Licensee is to pay for Patent Prosecution, Caltech will invoice the Licensee for all the costs of filing and prosecution Patent Rights. Invoices of costs will be due 60 days from
receipt 

3.     LICENSING  

	3.1
	Stanford
grants to Caltech the exclusive right to negotiate, execute, and administer any License Agreement covering Patent Rights, subject to the terms of this Agreement. Stanford
will not license Patent Rights unless this Agreement is terminated and there is no License Agreement in effect or in negotiation, in accordance with Article 9 (Termination).

	3.2
	Caltech
will diligently seek Licensee(s) for the commercial development of Patent Rights and will administer the License Agreement for the mutual benefit of the parties to this
Agreement and in the public interest.

	3.3
	Caltech
will have the final authority to enter into negotiations and execute License Agreement(s), subject to the terms of this Agreement. Caltech will provide Stanford with copies of
any License Agreement issued. Stanford will keep these documents and related documentation confidential in accordance with Article 8 (Confidentiality), except that Stanford may disclose the
existence of any License Agreement and may report royalties in aggregate.

	3.4
	Stanford
and Caltech retain the right, on behalf of themselves and all other non-profit academic research institutions, to practice the Patent Rights and use Technology
for any non-profit purpose, including sponsored research and collaborations. Caltech will ensure that Licensee agrees that Licensee has no right to enforce the Patent Rights against any
such institution. Stanford, Caltech, and any such other institution have the right to publish any information included in the Technology or Patent Rights. Any exclusive or field exclusive license
agreement entered into for said Patent Rights will include this provision of Paragraph 3.4.

	3.5
	Licenses
will disclaim all warranties as to the efficacy or noninfringement of the Patent Rights or Technology, and licenses will require Licensee to defend and indemnify Stanford and
Caltech from all liabilities and will require Licensee to include Stanford and Caltech under its insurance. In addition, each License Agreement (or option to negotiate a License Agreement) shall not
commit any rights in intellectual property developed by Dr. Quake or his laboratory after March 1, 2006.

	3.6
	Licenses
will include restrictions on the use of Stanford's and Caltech's name by the Licensee. Specifically, Licensee will not be permitted to identify Stanford or Caltech in any
promotional statement, or otherwise use the name of any Stanford or Caltech faculty member, employee, or student, or any trademark, service mark, trade name, or symbol of Caltech, Stanford or Stanford
Hospitals and Clinics, including the Stanford and Caltech name, unless Licensee has received Stanford's or Caltech's prior written consent, as the case may be. Permission to Licensee may be withheld
at Stanford's or Caltech's sole discretion. Each License Agreement shall also state that if Licensee wishes to identify HHMI or any HHMI employee (including Dr. Quake) in any promotional statement, or
otherwise use HHMI's name or that of any HHMI employee such as Dr. Quake, Licensee shall first obtain HHMI's (and Dr. Quake's, if applicable) prior written consent. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

3

 

	3.7
	This
Agreement does not create an agency relationship between the parties. 

4.     FINANCIAL TERMS  

	4.1
	For
as long as this Agreement is in effect, Caltech will pay Stanford [***] under this Agreement to be paid [***].

	4.2
	During
the life of this Agreement, Caltech and Stanford will be solely responsible for calculating and distributing to its respective inventors named on any patent applications or
patents contained in Patent Rights their share of Net Income in accordance with its own policy. 

5.     PATENT INFRINGEMENT  

	5.1
	If
Caltech or Stanford or an exclusive Licensee learns of the substantial infringement of any Patent Rights under this Agreement, then the party who learns of the infringement will
promptly call attention to the infringement in writing to the other parties and provide the other parties with reasonable evidence of the infringement.

	5.2
	Each
party will cooperate with the other in litigation proceedings instituted under this Agreement but at the expense of the party or parties bringing the suit. This litigation
(including settlement) will be controlled by the party initiating litigation. Monetary awards resulting from the litigation or any settlement thereof will be first used to reimburse the participating
parties for the cost of such action. Then to reimburse Caltech and Stanford for any Net Income owed in the form of royalties, and any remainder to the party initiating the action, or in the event of
multiple parties joining the action, in proportion to the expense borne by each party joining the action. 

6.     COMPLIANCE  

	6.1
	Caltech
and Licensee(s) shall comply with the rights of the U.S. Government under Title 35, United States Code, Section 200 et seq. 

7      NOTICE  

	7.1
	Any
notice or payment required to be given to either party shall be addressed as follows:

CALTECH:

Office of Technology Transfer

California Institute of Technology

1200 East California Boulevard (M/C 210-85)

Pasadena, California 91125

FAX No. (626) 365-2486

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

4

 

STANFORD:

Office of Technology Licensing

Stanford University

1705 El Camino Real

Palo Alto, CA 94306-1106

Fax No. (650) 725-7295

Email: info@otlmail.stanford.edu

Either party may notify the other in writing of a change of address or FAX number, in which event any subsequent communication relative to this Agreement shall be sent to the last said notified
address or number. All notices and communications relating to this Agreement will be deemed to have been given when received. 

8.     CONFIDENTIALITY  

	8.1
	If
either party discloses confidential information to the other party, the disclosing party will designate this information as confidential by appropriate written legend or
instruction, and the receiving party will:

	8.1(a)
	Use
the same degree of care to maintain the secrecy of the confidential information as it uses to maintain the secrecy of its own information of like kind; and

	8.1(b)
	Use
the confidential information only to accomplish the purposes of this Agreement.

	8.2
	Neither
party will disclose confidential information received from the other party except to its employees, inventors, customers, distributors and other agents who are bound to its by
similar obligations of confidence and only as required to accomplish the purposes of this Agreement.

	8.3
	Notwithstanding
anything in this Agreement to the contrary, Stanford will disclose to HHMI each License Agreement and option to license and such other documents or records relating to
this Agreement as HHMI may reasonably request, including without limitation any royalties in the form of equity allocable to Dr. Quake or any HHMI employees, subject in each case to HHMI's obligations
in place with Stanford to maintain them in confidence. 

9.     TERMINATION  

	9.1
	If
two years have passed from the effective date of this Agreement and no License Agreement is in effect or has been agreed upon in writing, including all material financial terms,
either party may terminate this Agreement for any reason upon at least 60 days' written notice to the other party, but in any event, not less than 60 days prior to the date on which
responses to any pending office actions need to be taken to preserve Patent Rights.

	9.2
	Termination
of this Agreement will not relieve either party of any obligation or liability accrued under this Agreement before termination or rescind any payments made or due before
termination.

	9.3
	Termination
of the Agreement will not affect any License Agreement granted under this Agreement; any License Agreement granted prior to termination will continue in full force and
effect. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

5

 

10.   LIFE OF THE AGREEMENT  

	10.1
	This
Agreement is effective from the Effective Date and will remain in effect for the life of the last-to-expire patent under Patent Rights, or in the event
no patent contained in Patent Rights issues or such patents or patent applications are abandoned, for a period of 17 years from the effective date of this Agreement, unless otherwise terminated
by operation of law or by acts of the parties in accordance with the terms of this Agreement.

	10.2
	Any
termination of this Agreement will not affect the rights and obligations set forth in the following Articles:

	8.
	Confidentiality

	9.
	Termination

	10.
	Life
of the Agreement

	11.
	Use
of Names

	13.
	Records
and Reports 

11.   USE OF NAMES  

	11.1
	Stanford
agrees that it shall not use the name of Caltech, or California Institute of Technology, in any advertising or publicity material, or make any form of representation or
statement which would constitute an express or implied endorsement by Caltech of any Licensed Product, and that it shall not authorize others to do so, without having obtained written approval from
Caltech, except as may be required by governmental law, rule or regulation.

	11.2
	Caltech
agrees that it shall not use the name of Stanford, or the Board of Trustees of the Leland Stanford Junior University, in any advertising or publicity material, or make any
form of representation or statement which would constitute an express or implied endorsement by Stanford of any Licensed Product, and that it shall not authorize others to do so, without having
obtained written approval from Stanford, except as may be required by governmental law, rule or regulation. 

12.   GOVERNING LAW  

	12.1
	This
Agreement will be governed by and interpreted, and its performance enforced, in accordance with California law, excluding any choice of rules that would direct the application
of the laws of another jurisdiction, except that the scope and validity of any patent application or patent will be governed and enforced by the laws of the applicable country of the patent
application or patent.

	12.2
	The
parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have
been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

6

 

13.   RECORDS AND REPORTS  

	13.1
	Caltech
shall keep complete, true and accurate accounts of all License Expenses and of all Net Income received by it from each licensee of the Patent Rights and shall permit Stanford
to examine its books and records in order to verify the payments due or owed under this Agreement.

	13.2
	Upon
request by Stanford, Caltech shall submit to Stanford an annual report setting forth the status of all patent prosecution, commercial development and licensing activity relating
to the Patent Rights for the preceding year. 

14.   COMPLETE AGREEMENT  

	14.1
	This
Agreement sets forth the complete agreement of the parties concerning the subject matter hereof. No waiver of or change in any of the terms hereof subsequent to the execution
hereof claimed to have been made by any representative of either party shall have any force or effect unless in writing, signed by duly authorized representatives of the parties.

	14.2
	HHMI
is an intended third-party beneficiary of Articles 1, 3, 8, and Paragraph 10.2 of this Agreement to the extent HHMI will own technology or intellectual property developed
by Dr. Quake or his laboratory on or after January 16, 2006 and wishes to confirm that such items developed after March 1, 2006 are not covered by this Agreement or the
transactions contemplated hereby. 

        IN WITNESS WHEREOF, the parties have caused this Agreement to be executed: 

	 	 	 	 	CALIFORNIA INSTITUTE OF

TECHNOLOGY (Caltech)
	

Date:	
 	

7/31/06
	
 	

By:	
 	

/s/ Frederic Farina

	 	 	 	 	Name:	 	Frederic Farina
	 	 	 	 	Title:	 	Asst VP, Office of Technology Transfer
	

Date:	
 	

Aug. 7, 2006
	
 	
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Stanford)
	 	 	 	 	By:	 	/s/ Katharine Ku

	 	 	 	 	Name:	 	KATHARINE KU

	 	 	 	 	Title:	 	DIRECTOR TECHNOLOGY LICENSING

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

7

 
Exhibit A

Licensed Patent Rights  

[***] 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

8

  

        CIT-4415 

 
 

INTER-INSTITUTIONAL AGREEMENT    
    

        This Inter-Institutional Agreement ("Agreement") is made and entered into this xxth day of July, 2006 ("Effective Date") by and between CALIFORNIA
INSTITUTE OF TECHNOLOGY ("Caltech"), a corporation duly organized and existing under the laws of California and having its principal office at 1200 East California Boulevard, Pasadena, California
91125, and THE UNIVERSITY OF CHICAGO, an institution of higher education having powers under the laws of the State of Illinois and having its principal office at 5555 South Woodlawn Avenue, Chicago
IL, 60637. 

 
 

RECITALS    
    

        WHEREAS, Professor Milan Mrksich has worked at the University of Chicago in the development of technology, further identified as Exhibit A; in
collaboration with the laboratory of Professor Stephen Quake at Caltech and Stanford; and 

        WHEREAS,
The University of Chicago wishes Caltech to represent The University of Chicago's interests in the filing, prosecution and maintenance of all patents covering inventions
described in Patent Rights; and 

        WHEREAS,
The University of Chicago wishes Caltech to represent The University of Chicago's interests in licensing of the Patent Rights; and 

        WHEREAS,
The University of Chicago and Caltech want the inventions described in Patent Rights to be patented and licensed to the fullest extent so the commercial products and other
benefits from licensing it can be enjoyed by the general public; 

        The
parties agree as follows: 

1.     DEFINITIONS  

	1.1
	"Patent(s)"
means rights under all domestic and foreign patents and patent applications listed in Exhibit A attached hereto and all patents and patent applications that
describe and claim inventions set forth in the invention disclosures listed on Exhibit A; and patents which issue on the applications listed in Exhibit A or any applications that claim
inventions set forth in the invention disclosures set for on Exhibit A; all reissues, reexaminations, renewals, extensions, divisionals, and continuations of the foregoing patents and patent
applications; and any foreign counterparts and any other forms of protection directed to the inventions described and claimed in the patents or patents or patent applications and inventions
disclosures listed in Exhibit A.

	1.2
	"Patent
Rights" means worldwide rights to the inventions described and claimed in the patent applications listed in Exhibit A; reissues, reexaminations, renewals, extensions,
divisionals, and continuations of the foregoing; and any foreign counterparts and any other forms of protection directed to the inventions described and claimed in the patent applications listed in
Exhibit A. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

1

 

	1.3
	"Technology"
means all proprietary information, know-how, procedures, methods, prototypes, designs, technical data and reports listed in Exhibit A that were in
existence on or prior to March 1, 2006 and are necessary or useful in the development of Licensed Products and which relate to the Licensed Products, but which are not the subject of the Patent
Rights. Subject to the foregoing, inventions which (i) are described and claimed in the applications for patents listed in Exhibit A and (ii) are not claimed in an issued patent
included in the Licensed Patent Rights shall be considered to be Technology.

	1.4
	"Net
Income" means royalties and fees and any other consideration, including but not limited to equity, received from licensing of Patent Rights less, where applicable, any
out-of-pocket expenses of the parties associated with Patent Rights or the License Agreement.

	1.5
	"Licensee"
means any party to a License Agreement with Caltech.

	1.6
	"License
Agreement" means any agreement entered into by Caltech on behalf of both The University of Chicago and Caltech that grants Licensee the right to make, use, offer to sell
and/or sell products or services covered by Patent Rights, or any agreement granting an option for such a license.

	1.7
	"Inventors"
means Stephen Quake of Caltech and Stanford, Jerrod Schwartz of Caltech and Stanford; Milan Mrksich of University of Chicago, either together or individually.

	1.8
	"Patent
Prosecution" means the preparation, filing, prosecution, maintenance and/or defense of Patent(s).

	1.9
	"License
Expenses" means all reasonable, out-of-pocket expenses incurred by Caltech related to Patent Prosecution. 

2.     PATENT PROSECUTION AND PROTECTION  

	2.1
	Caltech
may file patent applications covering the Patent Rights and will provide to The University of Chicago all serial numbers and filing dates, together with copies of all the
applications, including copies of all office actions, responses and all other communications from the U.S. Patent and Trademark Office.

	2.2
	Caltech
will, after consulting with The University of Chicago, and if necessary after consulting with Licensee, make an election whether, when, and in which countries, it wishes to
file foreign patent applications. Caltech will notify The University of Chicago in writing, of its election regarding foreign filing. If foreign patent applications are filed, Caltech will provide to
The University of Chicago copies of foreign patent applications and patent office actions as The University of Chicago may request in the course of prosecution.

	2.3
	Caltech
will record assignments of domestic Patent Rights in the United States Patent and Trademark Office and will provide The University of Chicago with a photocopy of each recorded
assignment. The University of Chicago inventors will assign to The University of Chicago and Caltech inventors will assign to Caltech.

	2.4
	Notwithstanding
any other provision of this Agreement, Caltech will not abandon the prosecution of any patent application (except for purposes of filing continuation applications) or
the maintenance of any Patent Rights without prior written notice to The University of Chicago in which case The University of Chicago may assume responsibility of the same.

	2.5
	Caltech
will promptly provide The University of Chicago with copies of all patents issued under Patent Rights. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

2

 

	2.6
	Caltech
will invoice The University of Chicago for reimbursement of one-third of the unreimbursed costs of filing and prosecuting Patent Rights during the term of this
Agreement, or, in the event a Licensee is to pay for Patent Prosecution, Caltech will invoice the Licensee for all the costs of filing and prosecution Patent Rights. Invoices of costs will be due
60 days from receipt. 

3.     LICENSING  

	3.1
	The
University of Chicago grants to Caltech the exclusive right to negotiate, execute, and administer any License Agreement covering Patent Rights, subject to the terms of this
Agreement. The University of Chicago will not license Patent Rights unless this Agreement is terminated and there is no License Agreement in effect or in negotiation, in accordance with
Article 9 (Termination).

	3.2
	Caltech
will diligently seek Licensee(s) for the commercial development of Patent Rights and will administer the License Agreement for the mutual benefit of the parties to this
Agreement and in the public interest.

	3.3
	Caltech
will have the final authority to enter into negotiations and execute License Agreement(s), subject to the terms of this Agreement. Caltech will provide The University of
Chicago with copies of any License Agreement issued. The University of Chicago will keep these documents and related documentation confidential in accordance with Article 8 (Confidentiality),
except that The University of Chicago may disclose the existence of any License Agreement and may report royalties in aggregate.

	3.4
	The
University of Chicago and Caltech retain the right, on behalf of themselves and all other non-profit academic research institutions, to practice the Patent Rights and
use Technology for any non-profit purpose, including sponsored research and collaborations. Caltech will ensure that Licensee agrees that Licensee has no right to enforce the Patent Rights
against any such institution. The University of Chicago, Caltech, and any such other institution have the right to publish any information included in the Technology or Patent Rights. Any exclusive or
field exclusive license agreement entered into for said Patent Rights will include this provision of Paragraph 3.4.

	3.5
	Licenses
will disclaim all warranties as to the efficacy or noninfringement of the Patent Rights or Technology, and licenses will require Licensee to defend and indemnify The
University of Chicago and Caltech from all liabilities and will require Licensee to include The University of Chicago and Caltech under its insurance. In addition, each License Agreement (or option to
negotiate a License Agreement) shall not commit any rights in intellectual property developed by Dr. Quake or his laboratory after March 1, 2006.

	3.6
	This
Agreement does not create an agency relationship between the parties. 

4.     FINANCIAL TERMS  

	4.1
	For
as long as this Agreement is in effect, Caltech will pay The University of Chicago [***] under this Agreement to be paid [***].

	4.2
	During
the life of this Agreement, Caltech and The University of Chicago will be solely responsible for calculating and distributing to its respective inventors named on any patent
applications or patents contained in Patent Rights their share of Net Income in accordance with its own policy. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

3

 

5.     PATENT INFRINGEMENT  

	5.1
	If
Caltech or The University of Chicago or an exclusive Licensee learns of the substantial infringement of any Patent Rights under this Agreement, then the party who learns of the
infringement will promptly call attention to the infringement in writing to the other parties and provide the other parties with reasonable evidence of the infringement.

	5.2
	Each
party will cooperate with the other in litigation proceedings instituted under this Agreement but at the expense of the party or parties bringing the suit. This litigation
(including settlement) will be controlled by the party initiating litigation. Monetary awards resulting from the litigation or any settlement thereof will be first used to reimburse the participating
parties for the cost of such action. Then to reimburse Caltech and The University of Chicago for any Net Income owed in the form of royalties, and any remainder to the party initiating the action, or
in the event of multiple parties joining the action, in proportion to the expense borne by each party joining the action. 

6.     COMPLIANCE  

	6.1
	Caltech
and Licensee(s) shall comply with the rights of the U.S. Government under Title 35, United States Code, Section 200 et seq. 

7      NOTICE  

	7.1
	Any
notice or payment required to be given to either party shall be addressed as follows:

CALTECH:

Office of Technology Transfer

California Institute of Technology

1200 East California Boulevard (M/C 210-85)

Pasadena, California 91125

FAX No. (626) 365-2486

THE
UNIVERSITY OF CHICAGO:

University of Chicago Office of Technology and Intellectual Property

5555 South Woodlawn Avenue, Suite 300

Chicago, Illinois 60637

Phone 773-702-1692

FAX 773-702-0741

Attention: Director of Technology Transfer

Either
party may notify the other in writing of a change of address or FAX number, in which event any subsequent communication relative to this Agreement shall be sent to the last said notified
address or number. All notices and communications relating to this Agreement will be deemed to have been given when received. 

8.     CONFIDENTIALITY  

	8.1
	If
either party discloses confidential information to the other party, the disclosing party will designate this information as confidential by appropriate written legend or
instruction, and the receiving party will:

	8.1(a)
	Use
the same degree of care to maintain the secrecy of the confidential information as it uses to maintain the secrecy of its own information of like kind; and

	8.1(b)
	Use
the confidential information only to accomplish the purposes of this Agreement. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

4

 

	8.2
	Neither
party will disclose confidential information received from the other party except to its employees, inventors, customers, distributors and other agents who are bound to its by
similar obligations of confidence and only as required to accomplish the purposes of this Agreement. 

9.     TERMINATION  

	9.1
	If
two years have passed from the effective date of this Agreement and no License Agreement is in effect or has been agreed upon in writing, including all material financial terms,
either party may terminate this Agreement for any reason upon at least 60 days' written notice to the other party, but in any event, not less than 60 days prior to the date on which
responses to any pending office actions need to be taken to preserve Patent Rights.

	9.2
	Termination
of this Agreement will not relieve either party of any obligation or liability accrued under this Agreement before termination or rescind any payments made or due before
termination.

	9.3
	Termination
of the Agreement will not affect any License Agreement granted under this Agreement; any License Agreement granted prior to termination will continue in full force and
effect. 

10.   LIFE OF THE AGREEMENT  

	10.1
	This
Agreement is effective from the Effective Date and will remain in effect for the life of the last-to-expire patent under Patent Rights, or in the event
no patent contained in Patent Rights issues or such patents or patent applications are abandoned, for a period of 17 years from the effective date of this Agreement, unless otherwise terminated
by operation of law or by acts of the parties in accordance with the terms of this Agreement.

	10.2
	Any
termination of this Agreement will not affect the rights and obligations set forth in the following Articles:

	8.
	Confidentiality

	9.
	Termination

	10.
	Life
of the Agreement

	11.
	Use
of Names

	13.
	Records
and Reports 

11.   USE OF NAMES  

	11.1
	The
University of Chicago agrees that it shall not use the name of Caltech, or California Institute of Technology, in any advertising or publicity material, or make any form of
representation or statement which would constitute an express or implied endorsement by Caltech of any Licensed Product, and that it shall not authorize others to do so, without having obtained
written approval from Caltech, except as may be required by governmental law, rule or regulation. How about the following as a replacement: "Neither Party may use the name of the other Party in any
way for advertising or publicity without the express written consent of the other Party, provided, however, that Caltech has the right to use the name of The University of Chicago within the context
of a License Agreement" ? 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

5

 

12.   GOVERNING LAW  

	12.1
	This
Agreement will be governed by and interpreted, and its performance enforced, in accordance with California law, excluding any choice of rules that would direct the application
of the laws of another jurisdiction, except that the scope and validity of any patent application or patent will be governed and enforced by the laws of the applicable country of the patent
application or patent.

	12.2
	The
parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have
been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. 

13.   RECORDS AND REPORTS  

	13.1
	Caltech
shall keep complete, true and accurate accounts of all License Expenses and of all Net Income received by it from each licensee of the Patent Rights and shall permit The
University of Chicago to examine its books and records in order to verify the payments due or owed under this Agreement.

	13.2
	Upon
request by The University of Chicago, Caltech shall submit to The University of Chicago an annual report setting forth the status of all patent prosecution, commercial
development and licensing activity relating to the Patent Rights for the preceding year. 

14.   INDEMNIFICATION  

	14.1
	Each
party shall indemnify and hold harmless the other party and its officers, directors, trustees, inventors, employees, students and agents, against any and all claims, suits,
losses, damages, costs, fees and expenses resulting from licensing of the Inventions to Licensees, including but not limited to any damages, losses or liabilities with respect to death or injury to
any person and damage to any property arising from either party's or any Licensee's negligence, willful misconduct or breach of any provision of this Agreement. This indemnification clause shall
survive the termination of this Agreement. 

15.   COMPLETE AGREEMENT  

	14.1
	This
Agreement sets forth the complete agreement of the parties concerning the subject matter hereof. No waiver of or change in any of the terms hereof subsequent to the execution
hereof claimed to have been made by any representative of either party shall have any force or effect unless in writing, signed by duly authorized representatives of the parties.

	14.2
	HHMI
is an intended third-party beneficiary of Articles 1, 3, 8, and Paragraph 10.2 of this Agreement to the extent HHMI will own technology or intellectual property developed
by Dr. Quake or his laboratory on or after January 16, 2006 and wishes to confirm that such items developed after March 1, 2006 are not covered by this Agreement or the
transactions contemplated hereby. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

6

 

        IN WITNESS WHEREOF, the parties have caused this Agreement to be executed: 

	 	 	 	 	CALIFORNIA INSTITUTE OF TECHNOLOGY (Caltech)
	

Date:	
 	

    
	
 	

By:	
 	

    

	 	 	 	 	Name:	 	Frederic Farina
	 	 	 	 	Title:	 	Asst VP, Office of Technology Transfer
	

Date:	
 	

    
	
 	
THE UNIVERSITY OF CHICAGO
	 	 	 	 	By:	 	    

	 	 	 	 	Name:	 	Alan Thomas
	 	 	 	 	Title:	 	Director of Technology Transfer, UCTech

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

7

 
 
 

Exhibit A
  
    Licensed Patent Rights    
    

        [***]

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

8

QuickLinks

Exhibit 10.12

INTER-INSTITUTIONAL AGREEMENT

RECITALS

INTER-INSTITUTIONAL AGREEMENT

RECITALS

Exhibit A Licensed Patent RightsQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.15    
    

 
 

LICENSE AND SUPPLY AGREEMENT    
    

effective
as of the 23rd day of April, 2007 ("Effective Date")

is entered into between 

PERKINELMER LAS, INC.

Having a principal place of business at 940 Winter Street,

Waltham, MA 02451

(hereinafter "PE") 

and 

HELICOS BIOSCIENCES CORPORATION

Having a principal place of business at One Kendall Square, Building 700,

Cambridge, MA 02139

(hereinafter "HELICOS") 

(each
of which is referred to as a "Party", and collectively referred to as the

"Parties") 

PREAMBLE  

        PE is the owner of the entire right, title and interest in and to the Licensed Patents, as defined below, and Helicos desires a license under the Licensed Patents
in the Field. PE is willing to grant such a license under the following terms and conditions. 

1.     Definitions  

        In this Agreement, unless the context otherwise requires: 

	1.1
	"Affiliate"
shall mean any entity that directly or indirectly controls, or is controlled by a Party to this Agreement. The term "control" as used herein means (a) in the case
of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; or (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities.

	1.2
	"Commercial
Use" shall mean sales to third parties by Helicos of a Licensed Product or Licensed Service.

	1.3
	"Confidential
Information" shall mean confidential or other proprietary information that is disclosed by either Party to the other Party under this Agreement, including, without
limitation, hardware and software designs, product specifications and documentation, business and product plans and other confidential business information whether in a written or
non-written format. Confidential Information shall be marked as confidential at the time of disclosure or otherwise designated as confidential by the disclosing Party within thirty
(30) days of disclosure. Confidential Information shall not include information which: (i) is or becomes public knowledge without any action by, or involvement of, the receiving Party;
(ii) is disclosed by the receiving Party with the prior written approval of the disclosing Party; (iii) is independently developed by the receiving Party without use of the disclosing
Party's Confidential Information; (iv) is intentionally disclosed by the disclosing Party about the disclosing Party's own information to a third party without restriction on disclosure;
(v) is rightfully received by the receiving Party from a third party without a duty of confidentiality. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

1

 
	1.4
	"Diagnostics"
shall mean a Licensed Product and/or the sale, or offer for sale thereof, requiring the registration or approval of the U.S. Food and Drug Administration of the Licensed
Product before the same may be sold or offered for sale in the United States.

	1.5
	"End-User"
means an unrelated third party, other than a distributor or other intermediary, who is the ultimate user of Licensed Product or ultimate recipient of Licensed
Service.

	1.6
	"Exploit"
shall mean to import, make, have made, use, sell, offer for sale, sell through distributors, develop, commercialize, seek necessary or desirable regulatory approvals,
export, transport, distribute, promote and market.

	1.7
	"Field"
shall mean life science research and Commercial Use, but specifically excludes all Diagnostics applications.

	1.8
	"Helicos
Instrument" shall mean hardware manufactured by or on the behalf of Helicos and sold by Helicos.

	1.9
	"Helicos
Proprietary Reagent" shall mean any reagent developed by Helicos and subject to claims in a patent application filed by Helicos and that do not infringe a Licensed Patent.

	1.10
	"Lead
Time" shall mean the time period between the acceptance by PerkinElmer of a Purchase Order and the delivery date of the Nucleotide Analog Products ordered under such Purchase
Order.

	1.11
	"Licensed
Patent" shall mean any and all patents and patent applications listed in Appendix A attached hereto. Any continuations, divisionals,
continuation-in-part, re-examination, reissue, and all foreign counterparts of the patents and patent applications listed in Appendix A shall also be
included within the Licensed Patents.

	1.12
	"Licensed
Product" shall mean chemical reagents sold by Helicos that contain a component that would, but for the license granted herein, infringe one or more Valid and Enforceable
Claim(s) of the Licensed Patents. For the avoidance of doubt, Licensed Products shall include all reagents sold by Helicos that are not a Helicos Proprietary Reagent, whether sold separately or
bundled together, as long as at least one reagent would, but for the license granted herein, infringe one or more Valid and Enforceable Claim(s) of the Licensed Patents, but shall not include
associated hardware.

	1.13
	"Licensed
Service" shall mean a service provided by Helicos that includes the use of a Licensed Product.

	1.14
	"Net
Sales" shall mean sales recognized by Helicos or its Affiliates under generally accepted accounting principles attributable to the sale of a Licensed Product or Licensed Service
(whether directly or indirectly, including sales via sublicensees, distributors, dealers etc) less deductions for returns, rebates, volume discounts, sales taxes and other taxes directly linked to the
sales, and customary duties and transportation costs incurred by Helicos or its Affiliates.

	1.15
	"Nucleotide
Analog Product" shall mean one of the products listed in Appendix B attached hereto, including any revisions, enhancements, modifications and/or replacements
thereto. The Nucleotide Analog Product or its use may be covered by one or more of the Licensed Patents. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

2

 
	1.16
	"Purchase
Order" shall mean a written purchase order, indicating the quantity of each Nucleotide Analog Product and its delivery date,that is delivered to PE in accordance with
Section 4.3.

	1.17
	"Purchase
Price" shall mean the amount to be paid by Helicos to PE for the Nucleotide Analog Products as determined in accordance with Section 4.1.

	1.18
	"Term"
shall mean the period beginning on the Effective Date and terminating on the date this Agreement is terminated under Article 10.

	1.19
	"Territory"
shall mean the world.

	1.20
	"Valid
and Enforceable Claim" shall mean a claim of a Licensed Patent that has not been held to be invalid or unenforceable by a court or administrative body of competent
jurisdiction in a proceeding from which no appeal can be or has been taken within the relevant time for doing so. 

Plurals
can be read in the singular and vice versa. 

2.     License Grant  

	2.1
	Grant
of License for Licensed Product

	(a)
	PE
hereby grants to Helicos and Helicos hereby accepts a non-exclusive, non-assignable, non-transferable, non-sublicensable, royalty
bearing, worldwide license under the Licensed Patents to Exploit Licensed Product and Licensed Service for End-Users for use in the Field in the Territory.

	(b)
	It
is understood by the Parties that this license grant of Section 2.1 carries with it an implied license to End-Users of Helicos to use the Licensed Product or
Licensed Service in the Field but not to resell the Licensed Product or Licensed Service.

	(c)
	Helicos
shall provide direct End-User customer support.

	2.2
	Royalty.
This license grant of this Article 2 is subject to the payment of the royalty fees set forth in Article 3.

	2.3
	Product
Marking. The rights granted in this Article 2 above are conditioned on Helicos including in every manual (or the
equivalent thereof) for every Licensed Product or Licensed Service on and after the Effective Date, in every printed catalog describing the Licensed Product or Licensed Service within six
(6) months from and after the Effective Date, and in the electronic media version of Helicos' catalog within one (1) week from and after the Effective Date, the following notice: 

"Limited Use License for End Users
  For RESEARCH USE ONLY, NOT FOR DIAGNOSTIC PURPOSES. End user does not have a right to resell or transfer the nucleotide analog components of this kit either
alone or as
components of another product. No other rights are conferred and other uses are strictly prohibited."

	2.4
	Limitations.
The license grant set forth in Section 2.1 above does not include the right by Helicos to sell a stand-alone Nucleotide Analog Product other than (a) for
use on a Helicos Instrument or (ii) as a component of or replacement part of a Licensed Product. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

3

 

3.     Royalty Payments and Accounting  

	3.1
	Royalty.
Helicos shall pay to PE: i) [***] of Net Sales of Licensed Products and Licensed Services for the first [***] of Net
Sales of Licensed Products or Licensed Services by Helicos; ii) [***] Net Sales by Helicos of Licensed Products and Licensed Services between
[***], and iii) thereafter [***] of Net Sales by Helicos of Licensed Products and Licensed Services in excess of [***]
for the remaining term of this Agreement. For the avoidance of doubt, the payment calculations under this Paragraph shall be based upon a cumulative total of Net Sales and shall not be reset on an
annual or any other basis.

	3.2
	Payment.
Payments under this Article 3 shall be made by Helicos within thirty (30) calendar days of the last day of each calendar year quarter based upon Net Sales in
the preceding calendar year quarter, with each calendar year quarter ending on the last day of March, June, September, and December.

	3.3
	Records.
Helicos shall keep complete and accurate records of Net Sales in accordance with generally accepted accounting principles. Such records shall be available to PE and its
auditor, or a third party mutually agreeable to PE and Helicos, for inspection, at PE's expense, during normal business hours for three (3) years after the end of the relevant royalty period.
Notwithstanding the foregoing, if such inspection reveals that reported royalties have been understated by more than five percent (5%), then Helicos shall reimburse PE for reasonable expenses incurred
by PE, or its designee, for such inspection. 

4.     Purchase Price and Nucleotide Analog Product Delivery  

	4.1
	Purchase
Price. Throughout the Term, the Purchase Price for any Nucleotide Analog Product shall be based on yearly quotes negotiated between the Parties. The current Purchase Price is
set forth in Quote No. 62219 (attached hereto as Appendix C), which shall remain in effect until its expiration on [***]. After [***], and at its
sole option, PE can alter the Purchase Price in line with market based pricing adjustments.

	4.2
	Taxes.
Helicos's Purchase Price does not include any applicable sales, use, service, value added, or like taxes, however designated, levied against the sale, licensing, delivery or
use of the Nucleotide Analog Products. Helicos shall pay all such taxes imposed on the Nucleotide Analog Products, and, when PE has the legal obligation to collect such taxes, the appropriate amount
shall be added to Helicos's invoice and paid by Helicos. Helicos shall not be liable for any taxes based on Helicos's net income or for which it has provided to PE an appropriate exemption certificate
for the delivery jurisdiction, provided, however, that Helicos shall promptly notify PE of any amendment or revocation of such certificate.

	4.3
	Purchase
Order Procedure. All orders for Nucleotide Analog Products submitted by Helicos shall be initiated by a written Purchase Order sent to PE and requesting a delivery date
during the Term. No order shall be binding upon PE until a Purchase Order has been accepted by PE in writing, and PE shall have no liability to Helicos with respect to Purchase Orders that are not
accepted, except as otherwise provided herein. PE shall notify Helicos of the acceptance or rejection of a Purchase Order and of the accepted delivery date for accepted orders within five
(5) business days after receipt of the Purchase Order. If Helicos is not notified of PE's acceptance or rejection within five (5) business days of receipt of the Purchase Order by PE,
the Purchase Order shall be deemed accepted by PE. Helicos's Purchase Orders submitted to PE with respect to the Nucleotide Analog Products to be purchased hereunder shall be governed by the terms of
this Agreement. Nothing contained in any such Purchase Order shall in any way modify such terms of purchase or add any additional terms or conditions except as otherwise agreed in writing by the
Parties. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

4

 
	4.4
	Forecast.
Helicos shall, on a quarterly basis, provide PE with a six (6) month non-binding rolling projection of orders by Helicos of the Nucleotide Analog Products
("Forecast"). PE cannot guarantee that additional amounts of the Nucleotide Analog Products submitted on the Forecast will be available for purchase by Helicos. Helicos commits to purchasing at least
ninety percent (90%) of the amount of Nucleotide Analog Products submitted for the first three (3) months of the rolling forecast; however, notwithstanding any other provision contained herein,
the Parties acknowledge and agree that the Forecast can in no way be construed as a commitment on Helicos's part to purchase one hundred percent (100%) of the amount of Nucleotide Analog Products
submitted on the Forecast.

	4.5
	Lead
Time. To facilitate PE's production scheduling, Helicos shall submit Purchase Orders to PE consistent with a Lead Time of sixty (60) calendar days.

	4.6
	Payment.
Helicos shall make full payment of the Purchase Price for the Nucleotide Analog Products to PE in United States dollars, net thirty (30) calendar days from Helicos's
receipt of an undisputed invoice from PE. In the event that Helicos fails to make payments when due, PE shall notify Helicos in writing of the non-payments, and Helicos shall have twenty
(20) calendar days to cure the non-payment. In the event Helicos fails to cure such non-payment, such non-payment will be considered a material breach by
Helicos, and PE may alter terms of payment, suspend credit, withhold shipment, and/or terminate this Agreement.

	4.7
	Shipping.
All orders are F.O.B. factory. All Nucleotide Analog Products delivered pursuant to the terms of this Agreement shall be delivered by Helicos's standard carrier. Upon
delivery by PE to the carrier, the Nucleotide Analog Products shall be deemed delivered in accordance with the Purchase Order, and all title, ownership, and risk of loss or damage with respect to the
Nucleotide Analog Products shall pass to Helicos. All freight, insurance, taxes, and other shipping expenses shall be paid by Helicos. Items shipped after their scheduled delivery date will be shipped
by PE on an expedited overnight basis with the surcharge for such expedited overnight delivery being at PE's sole expense.

	4.8
	Inspection.
Helicos shall use reasonable efforts to inspect all Products and to furnish to PE, in writing, any claim that Helicos may have in connection with such Products within
30 days of receipt, for any Material Defect in the Nucleotide Analog Product. Within thirty (30) days of receipt of such written claim, and upon Helicos's return to PE, at PE's sole
expense, of the defective Nucleotide Analog Product, PE shall, at its sole option, repair or replace the Nucleotide Product or provide credit of the Purchase Price to Helicos. Such remedy shall be
Helicos's sole remedy for defective product. 

5.     Independent Contractors  

        The relationship of PE and Helicos established by this Agreement is that of independent contractors, and nothing contained in this Agreement shall be construed to
(i) give either Party the power to direct and control the day-to-day activities of the other, (ii) constitute the Parties as partners, joint venturers,
co-owners or otherwise as participants in a joint or common undertaking, or (iii) allow either Party to create or assume any obligation on behalf of the other Party for any purpose
unless expressly provided herein. Except as set forth in Article 10, nothing in this Agreement shall preclude either Party from developing, manufacturing, marketing, selling, leasing or
maintaining any products to or for any other customer, including, without limitation, end-users, original equipment manufacturers or other resellers. 

6.     Limited Warranty  

	6.1
	Nucleotide
Analog Products. PE warrants that the Nucleotide Analog Products shipped under this Agreement will be free from any defects in material and workmanship. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

5

 
	6.2
	Disclaimer.
PE MAKES NO WARRANTY OF ANY OTHER KIND, EITHER EXPRESS OR IMPLIED, AND SPECIFICALLY NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE LICENSED
PRODUCTS MAY BE USED WITHOUT INFRINGING THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTIES. NOTIFICATION OF ANY BREACH OF A PE WARRANTY MUST BE MADE TO PE IN WRITING WITHIN SIXTY
(60) DAYS OF RECEIPT OF LICENSED PRODUCT. NO CLAIM SHALL BE HONORED IF HELICOS FAILS TO NOTIFY PE WITHIN THE PERIOD SPECIFIED. THE SOLE AND EXCLUSIVE REMEDY OF HELICOS FOR ANY LIABILITY OF PE
OF ANY KIND INCLUDING LIABILITY BASED UPON WARRANTY (EXPRESS OR IMPLIED WHETHER CONTAINED HEREIN OR ELSEWHERE), STRICT LIABILITY, CONTRACT, OR OTHERWISE IS LIMITED TO THE REPLACEMENT OF THE LICENSED
PRODUCT OR THE REFUND OF THE INVOICE PRICE THEREOF. PE SHALL NOT IN ANY CASE BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 

7.     Confidentiality  

        During the Term and for a period of five (5) years following the expiration or earlier termination of this Agreement, the Parties agree to observe complete
confidentiality with respect to the Confidential Information, and to make all reasonable efforts not to disclose, or permit any third party or entity access to, the Confidential Information (or any
portion thereof) without the prior written permission of
the other Party (except such disclosure or access which is required to perform any obligations under this Agreement) and to ensure that any employees, or any third parties who obtain access to the
Confidential Information, are advised of the confidential and proprietary nature thereof and are prohibited by a written agreement from copying, utilizing or otherwise revealing the Confidential
Information. Without limiting the foregoing, the Parties agree to employ with regard to the Confidential Information procedures no less restrictive than the strictest procedures used by it to protect
its own confidential and proprietary information. Neither Party may use the Confidential Information for any purpose other than to fulfill its obligations under this Agreement. If either Party is
required to disclose pursuant to any judicial or governmental order, then the receiving Party must give the disclosing Party sufficient prior notice to contest such order. Notwithstanding the
foregoing, either party may disclose this Agreement with financial terms redacted to Government agencies or as otherwise required by law or regulation. 

8.     Indemnification and Insurance  

	8.1
	Indemnification.
PE and its Affiliates, and their directors, officers, employees and agents shall have no liability for damages incurred by Helicos resulting from actual or threatened
claims (including claims of inducement to infringe, demands, costs, damages, settlements, and liabilities (including all reasonable attorneys' fees and court costs)) of any kind whatsoever, regardless
of the form of such claims, relating to or arising out of the use, manufacture and/or sale by Helicos of Licensed Product or Licensed Services, and Helicos shall indemnify, defend, and hold harmless
PE and its Affiliates, and their directors, officers, employees and agents against all such claims except to the extent any such claim is shown by Helicos to have been caused directly and solely by
the gross negligence or willful misconduct of PE.

	8.2
	Insurance.
Helicos shall carry and maintain in force as long as its indemnification obligations remain in force, at Helicos's expense, insurance of the type and of the minimum
coverage limits as follows:

	(a)
	Damage,
including Contractual Liability, to cover Helicos' obligations under this Agreement, in a combined single limit—$2,000,000 per occurrence and a maximum of
$3,000,000 per annum. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

6

 

	(b)
	Other
insurance appropriate for Helicos' business or required by law. 

9.     Alleged Infringement of Licensed Patents  

        Helicos shall advise PE promptly upon its becoming aware of any third party's infringement of the Licensed Patents. PE shall at all times remain the owner of the
Licensed Patents with the sole right to enforce the Licensed Patents. 

10.   Termination  

	10.1
	Term.
This Agreement will become effective upon signature by both Parties and, unless terminated sooner as provided herein below or by mutual agreement, will remain in force and will
expire upon the expiration of the last to expire of the Licensed Patents on a country-by-country basis.

	10.2
	Termination
for Cause. Failure by either Party to this Agreement to comply with any of the obligations and conditions contained herein shall entitle the other Party to give the Party
in default written notice requiring it to cure such default. If the default is not remedied within sixty (60) days after receipt of such notice, the notifying Party shall be entitled, without
prejudice to any of its other rights conferred on it by this Agreement, to terminate the entire Agreement by giving notice to take effect immediately. The right of either Party to terminate the entire
Agreement as provided herein shall not be affected in any way by its waiver of or failure to take action with respect to any previous default.

	10.3
	Termination
for Insolvency. This Agreement shall terminate, upon notice by either Party, (i) if the other Party files voluntary bankruptcy proceedings, (ii) if
involuntary insolvency, receivership or bankruptcy proceedings instituted against the other Party are not dismissed within sixty (60) calendar days of such institution, (iii) upon the
other Party's making an assignment for the benefit of creditors, or (iv) upon the other Party's dissolution or ceasing to do business.

	10.4
	Termination
by either Party. Either Party may terminate this Agreement with a ninety (90) day prior written notice to the other Party.

	10.5
	Fulfillment
of Orders upon Termination. Upon termination of this Agreement for other than Helicos's material default or insolvency, PE shall continue to fulfill, subject to the terms
of Article 4, all Purchase Orders accepted by PE prior to the effective date of termination.

	10.6
	Survival.
The provisions of Articles 1, 5, 6, 8, 9, 10, 11, and 12 shall survive the expiration or earlier termination of this Agreement for any reason. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

7

   11.   Miscellaneous  

	11.1
	Amendment.
No amendments, changes, modifications or alterations of this Agreement shall be binding upon either party unless in writing and signed by both parties.

	11.2
	Headings.
All titles and captions in this Agreement are for convenience only and shall not be interpreted as having any substantive meaning.

	11.3
	Severability.
In the event that a court of competent jurisdiction holds that a particular provision or requirement of this Agreement is in violation of any law, such provision or
requirement shall not be enforced but replaced by a valid and enforceable provision or requirement which will achieve as far as possible the economic business intentions of the parties. All other
provisions and requirements of this Agreement, however, shall remain in full force and effect.

	11.4
	Entire
Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter herein and merges all prior discussions between them.
No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the Party to be charged.

	11.5
	Consents
and Approval. Except where expressly provided as being in the discretion of a Party, where approval, acceptance, consent or similar action by either Party is required under
this Agreement, such action shall not be unreasonably delayed or withheld. An approval or consent given by a Party under this Agreement shall not relieve the other Party from responsibility for
complying with the requirements of this Agreement, nor shall it be construed as a waiver of any rights under this Agreement, except as and to the extent otherwise expressly provided in such approval
or consent. Each Party shall, at the request of the other Party, perform those actions, including executing additional documents and instruments, reasonably necessary to give full effect to the terms
of this Agreement.

	11.6
	Mutually
Negotiated. The Parties agree that the terms and conditions of this Agreement (including any perceived ambiguity herein) shall not be construed in favor of or against any
Party by reason of the extent to which any Party or its professional advisors participated in the preparation of the original or any further drafts of this Agreement, as each Party has been
represented by counsel in its negotiation of this agreement and it represents their mutual efforts. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

8

 
	11.7
	Notices.
All notices and other communications hereunder shall be in writing and shall be deemed effective when delivered by hand or by facsimile transmission, when telexed or upon
receipt when mailed by registered or certified mail (return receipt requested), postage prepaid, to the Parties at the addresses and fax numbers specified as follows, or to any address and fax number
later provided by one party to the other: 

	PE	 	Helicos
	

PerkinElmer LAS, Inc.

Attn: President

940 Winter Street

Waltham, MA 02451

FAX: (781) 663-5972	
 	

Helicos BioSciences Corporation

One Kendall Square, Bldg. 700

Cambridge, MA 02139

Attn: Mark Solakian
	

With a copy to:	
 	

 
	

PerkinElmer LAS, Inc.

Attn: General Counsel

940 Winter Street

Waltham, MA 02451

FAX: (781) 663-5969	
 	

 

	11.8
	Force
Majeure. Except for the obligation to make payments, neither Party will be liable for any failure or delay in its performance under this Agreement due to any cause beyond its
reasonable control, including acts of war, acts of God, earthquake, flood, fire, embargo, riot, sabotage, labor shortage or dispute, governmental act, or failure of third party power or
telecommunications networks, provided that the delayed Party: (a) gives the other Party prompt notice of such cause, and (b) uses its reasonable commercial efforts to promptly correct
such failure or delay in performance. Notwithstanding the foregoing, if such event causes a delay in performance of more than sixty (60) days, the unaffected Party shall have the right to
terminate this Agreement without penalty upon written notice at any time prior to the affected Party's resumption of performance.

	11.9
	Assignment
and Binding Effect. Neither Party shall assign this Agreement to any third party without the prior written consent of the other Party; provided, however, that either party
may assign this Agreement to an Affiliate or a legal successor in interest to all or substantially all of the business or assets of such party without the prior written consent of the other party.
This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their permitted successors and assigns.

	11.10
	Legal
Expenses. The prevailing Party in any legal action brought by one Party against the other and arising out of this Agreement shall be entitled, in addition to any other rights
and remedies it may have, to reimbursement for its expenses, including court costs and reasonable attorneys' fees.

	11.11
	Counterparts.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

	11.12
	Publicity.
Neither party shall issue a press release or disclose publicly the terms of this Agreement without the prior written approval of the other party except as required by
law, Government agencies or court orders. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

9

 
	11.13
	Construction.
The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction shall
be applied against either Party. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the
context requires otherwise. Any reference herein to "including" shall be interpreted as "including without limitation". Any reference to any Article, Section or paragraph shall be deemed to refer to
an Article, Section or paragraph of this Agreement, unless the context clearly indicates otherwise.

	11.14
	Conflict.
Notwithstanding any other provision contained herein, in the event of any conflict between the terms and conditions of this Agreement and any exhibits and/or appendices
attached hereto or referenced herein, the terms and conditions of this Agreement shall control and prevail.

	11.15
	Waiver.
No delay or omission by either Party to exercise any right or power it has under this Agreement shall impair or be construed as a waiver of such right or power. A waiver by
any Party of any breach of any covenant or provision of this Agreement shall not be construed to be a waiver of any succeeding breach of any other covenant or provision. All waivers must be in writing
and signed by the Party waiving its rights. 

12.   Governing Law and Jurisdiction  

        Any dispute under this Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to its conflict of laws provisions and each
party agrees to submit to the jurisdiction of the appropriate court in Massachusetts. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

10

 

        IN
WITNESS WHEREOF the Parties have entered into this Agreement as of the Effective Date. 

	 	 	PerkinElmer LAS, Inc.
	

 	
 	

By:	
 	

/s/ Kenneth S. King

	

 	
 	

Title:	
 	

Vice President and General Manager Molecular Medicine PerkinElmer Life and Analytical Sciences
	

 	
 	

Date:	
 	

 
	

 	
 	
Helicos BioSciences Corporation
	

 	
 	

By:	
 	

/s/ Thomas Meyers

	

 	
 	

Title:	
 	

Vice President and Chief Patent Counsel
	

 	
 	

Date:	
 	

April 23, 2007

       

       

       

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

11

 
Appendix A  

[***]

       

       

      

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

12

 
Appendix B  

[***] 

  

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

13

 
Appendix C  

Customer Services Quotation  

	Please reply to: PerkinElmer Life and Analytical Sciences

549 Albany Street, Boston, MA 02188

US: (617) 350-9400

International: (617) 350-9076

Fax: (617) 542-4330

Date: 01/29/07	 	In response to your inquiry, we are pleased to offer this quotation on the product(s) you require. Unless otherwise stated, process and delivery specified will remain open for a period of ninety (90) days from the date of
this quotation. Orders placed are subject to acceptance by PerkinElmer Life and Analytical Sciences, Inc., TERMS: NET 30 DAYS
	

To:	
 	

Dr. Philip R. Buzby

Helicos BioSciences Corp.

Building 200

One Kendall Square

Cambridge MA 02139	
 	

Ref#: 62219

PerkinElmer Quotation: 62219

Shipping Method: Air Express

Shipping Charges: Included

Shipping Point: dest

By: Patrice Fiore
	

 	
 	

Phone: 617-551-4750	
 	

Fax: 617-551-4751

 

	Description
 
	 	Quantity
	 	U/M
	 	Price

	Product Name: [***]	 	[***]	 	Lot	 	 

Specific Activity: N/A 

Catalog
number: [***] 

Delivery
ARO: 1 to 1 Week(s) 

Radiochemical
Purity >= N/A 

Other
Analysis: 

Optical
Purity: N/A 

Determined
By: 

Recommended
Shipping Solvent: N/A 

Recommended
Concentration: N/A 

Shipped
on (ice type): 

Comments:
[***] 

	NOTE: This quotation is subject to revision of synthetic details.	 	AGREED TO AND ACCEPTED:
	

IMPORTANT INFORMATION	
 	

BY:
	 	 	TITLE:
	 	 	DATE:
	This quotation includes all of the provisions on the face hereof and delivered herewith. Only such instructions, terms and conditions shall constitute the agreement between the parties hereto. The acceptance
copy must be signed and returned to: PerkinElmer Life and Analytical Sciences	 	 
	

This service is performed exclusively for purposes of scientific experimentation, analysis or chemical research. The products of this service are for laboratory use for research purposes.	
 	

 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF
THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

14

QuickLinks

Exhibit 10.15

LICENSE AND SUPPLY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]